GSK and Relation Therapeutics Sign Up to $110 Million AI Drug Discovery Deal
Key Insights
GSK and Relation Therapeutics (search) entered a research collaboration valued at up to $110 million to leverage AI for drug target identification.
Relation will generate large-scale human cellular datasets to train AI foundation models, including its proprietary MORGAN platform.
The collaboration builds on an earlier partnership between the two companies focused on fibrotic diseases and osteoarthritis.
British biotech firm Relation Therapeutics (search) announced on Wednesday that it has entered into a research collaboration with GSK worth up to $110 million, aimed at generating human cellular datasets and training artificial intelligence models to identify potential new drug targets.
The deal, reported on July 30, underscores the growing role of AI in pharmaceutical research and development as major drugmakers seek to improve the efficiency and success rate of early-stage discovery.
Collaboration Details and the MORGAN Platform
Under the terms of the agreement, Relation Therapeutics (search) will generate large-scale datasets that reveal how human cells respond to genetic and drug interventions. These datasets will be used to train AI foundation models, including Relation's proprietary MORGAN platform. The MORGAN platform is designed to harness machine learning approaches to uncover novel biological insights and accelerate the identification of promising therapeutic targets.
The collaboration builds on an earlier partnership between GSK and Relation Therapeutics (search), which was focused on fibrotic diseases and osteoarthritis. The expanded scope of the new agreement signals confidence in the initial results and a shared commitment to integrating computational approaches deeper into the drug discovery process.
GSK's Strategic Push into AI-Driven R&D
GSK has been steadily increasing its investment in research and development as it works to strengthen its drug pipeline. The company has also been expanding the use of artificial intelligence to improve both the efficiency and success rate of drug discovery. This latest collaboration with Relation Therapeutics (search) aligns with that broader strategy, positioning GSK to leverage cutting-edge machine learning techniques in the search for new medicines.
The $110 million deal represents a significant commitment to AI-enabled target discovery and highlights the pharmaceutical industry's ongoing shift toward data-driven approaches in preclinical research.